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Abstract
The occurrence of seizures in childhood is often associated with neurodevelopmental impairments and school
underachievement. Common genetic variants associated with epilepsy have been identified and epigenetic
mechanisms have also been suggested to play a role. In this study, we analyzed the association of genome-wide
blood DNA methylation with the occurrence of seizures in ~ 800 children from the Avon Longitudinal Study of
Parents and Children, UK, at birth (cord blood), during childhood, and adolescence (peripheral blood). We also
analyzed the association between the lifetime occurrence of any seizures before age 13 with blood DNA
methylation levels. We sought replication of the findings in the Generation R Study and explored causality using
Mendelian randomization, i.e., using genetic variants as proxies. The results showed five CpG sites which were
associated cross-sectionally with seizures either in childhood or adolescence (1–5% absolute methylation difference
at pFDR < 0.05), although the evidence of replication in an independent study was weak. One of these sites was
located in the BDNF gene, which is highly expressed in the brain, and showed high correspondence with brain
methylation levels. The Mendelian randomization analyses suggested that seizures might be causal for changes in
methylation rather than vice-versa. In conclusion, we show a suggestive link between seizures and blood DNA
methylation while at the same time exploring the limitations of conducting such study.
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Background
Seizures are episodes of abnormal excessive or syn-
chronous neuronal activity in the brain. When associ-
ated with a febrile illness, they affect 2–4% of children
under 6 years of age in Europe and the USA, with the
highest incidence in underdeveloped and rural areas
reaching 14% in some areas [1, 2]. The most common
age for seizures to occur is at 18 months of age and chil-
dren that experienced seizures are at risk of developing
epilepsy. The incidence of epilepsy in children ranges
from 41 to 187/100,000 persons per year [2]. Seizures
and epilepsy are associated with neurodevelopmental
conditions, such as autism spectrum disorders [3],
attention-deficit hyperactivity disorder, and cognitive
impairment [4–7]. Moreover, epilepsy with or without
intellectual impairment is associated with low academic
achievement [8].
The two largest genome-wide association studies to
date (~ 8600 individuals with epilepsy versus ~ 26000
controls and ~ 15,200 individuals with epilepsy versus ~
29,600 controls) have identified a total of 24 genetic var-
iants associated with epilepsy [9, 10]. Some of these loci
are located in the proximity of candidate genes for epi-
lepsy, for instance those coding for ion-channel subunits,
and their relevance for epilepsy is supported by other re-
search in humans and animals. As it is likely that other
factors may also underlie the disease, it has been sug-
gested that epigenetic mechanisms such as DNA methy-
lation are also involved in the onset of seizures [11]. In
line with this hypothesis, genetic markers for epilepsy
were found to be enriched in histone modification
markers, suggesting epigenetic regulation of gene tran-
scription [9]. The association between seizures and DNA
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methylation has been investigated in studies involving
humans and other animals, although these studies relied
on small sample sizes or on a candidate gene approach.
There are different types of epilepsy syndromes depend-
ing on the age of onset (e.g., childhood or adolescence),
whether the seizures are predominantly characterized by
a focal or generalized onset, and whether there are
known causes (e.g., genetic or trauma) [12]. Mesial tem-
poral lobe epilepsy is one of the most common and most
studied forms of epilepsy [13]. A recent study comparing
blood DNA methylation in 30 adult patients with mesial
temporal lobe epilepsy and 30 controls identified 216
differentially methylated sites between the two groups,
including sites on genes involved in ion binding and
metabolic activity [14]. DNA methylation differences
have also been observed in lymphoblastoid cell lines de-
rived from epileptic patients, both when DNA methyla-
tion was measured globally using antibody capture and
in the BRD2 gene promoter [15]. Another study that
reanalyzed these data discovered differential DNA
methylation in non-coding RNAs [16]. Furthermore, al-
terations in DNA methylation were present in the
hippocampus of epileptic patients compared to controls
[17]. A study adopting a rat model of chronic epilepsy
corroborated these findings by revealing genome-wide
differences in DNA methylation compared to control
rats [18].
Typically, in association studies, it is difficult to assess
the causality of any identified association due to the po-
tential for confounding and/or for reverse causation. So-
cioeconomic status, for instance, is associated with
genome-wide changes in DNA methylation [19] and
with increased risk for seizures/epilepsy [20], suggesting
that socioeconomic factors could be confounding the as-
sociation between DNA methylation and seizures. With
respect to reverse causation, case-control studies that ex-
amined DNA methylation after epilepsy had already
been diagnosed might have observed changes that were
directly caused by the seizure events. For instance, labora-
tory animal studies have shown altered gene expression
after induced seizures [21]. Mendelian randomization, a
technique that uses the genetic information associated
with an exposure to estimate the causal effect of the ex-
posure on an outcome, can circumvent these limitations
under certain assumptions [22].
In this study, we (1) investigated the genome-wide as-
sociation of DNA methylation with the occurrence of
seizures from birth throughout childhood and adoles-
cence in peripheral blood samples from a prospective
birth cohort, (2) carried out replication analyses in an in-
dependent study sample, (3) explored the correspond-
ence with brain tissue DNA methylation at the same
genomic locations to investigate whether these associa-
tions have neurodevelopmental relevance, and (4)
performed bi-directional Mendelian randomization to
unravel causal links between peripheral blood DNA
methylation and seizures. Finally, we explored the poten-
tial health consequences of a seizure-associated DNA
methylation profile. For an overview on our analysis
plan, see Fig. 1.
Materials and methods
Study population
The discovery analyses were conducted in the Avon
Longitudinal Study of Parents and Children (ALSPAC),
a large prospective cohort study that recruited 14,541
pregnant women, resident in Avon, UK with expected
delivery dates between the 1st of April 1991 and the 31st
of December 1992 [23, 24]. Of these initial pregnancies,
there were 14,062 live births and 13,988 children who
were alive at 1 year of age. The study website contains
details of all the data that are available through a fully
searchable data dictionary (http://www.bris.ac.uk/alspac/
researchers/data-access/data-dictionary/).
Written informed consent has been obtained for all
ALSPAC participants. Ethical approval for the study was
obtained from the ALSPAC Ethics and Law Committee
and the Local Research Ethics Committees.
Seizure data
The diagnosis of seizures and epilepsy is usually based
on the pattern of seizures, age of onset, and electroen-
cephalographic and imaging features, and potentially the
history of comorbidities as well as genetic and/or meta-
bolic screening [25]. In our ALSPAC population study,
we relied on data taken from questionnaires adminis-
tered to the mothers at four time points: 18 months, 8
years, 11 years, and 13 years. The following questions
were asked at each of these ages:
18 months: “Has he/she ever had any form of convul-
sion/fit/seizure or other turn in which consciousness
was lost or any other part of the body made an abnormal
movement?’,
8 years: “Has child had a convulsion/fit/seizure since
7th birthday?”,
11 years: “Has child had a convulsion/fit/seizure where
consciousness or abnormal movement was lost since 9th
birthday?”, and
13 years: “Has she ever had a seizure, fit or a
convulsion?”.
This allowed us to address proximal and distal (i.e.,
lifetime until age 13) associations between DNA methy-
lation and experience of seizures. The seizures reported
in our study could have included any type of seizure that
might not be considered epilepsy, such as febrile seizures
typically experienced before 6 years of age and single oc-
currences provoked by trauma. Alternatively, they could
be recurring seizures of the types typical of an epilepsy
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syndrome. However, we did not have access to the infor-
mation on the clinical diagnoses in relation to epilepsy
in the study participants.
DNA methylation data
In ALSPAC, blood from 1018 mother-child pairs were se-
lected for analysis as part of the Accessible Resource for In-
tegrative Epigenomic Studies (ARIES, http://www.
ariesepigenomics.org.uk/) [26]. Following DNA extraction,
samples were bisulphite converted using the Zymo EZ
DNA Methylation™ kit (Zymo, Irvine, CA, USA), and
genome-wide methylation was measured using the Illumina
Infinium HumanMethylation450 (HM450) BeadChip. The
arrays were scanned using an Illumina iScan, with initial
quality review using GenomeStudio. ARIES was pre-
processed and normalized using the meffil R package [27].
ARIES consists of from mother-child pairs measured at five
time points (three time points for children: birth, childhood,
and adolescence; and two for mothers: during pregnancy
and at middle age), although only children’s profiles were
used in the current study. Low quality profiles were
removed from further processing, and the remaining 4593
profiles were normalized using the Functional Normalization
algorithm [28] with the top 10 control probe principal com-
ponents. Full details of the pre-processing and normalization
of ARIES have been described previously [27]. Further pre-
Fig. 1 Analysis overview
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processing specific to the current study included removal of
probes not passing background detection (p > 0.05) and
probes on the X or Y chromosome. To reduce the impact of
outliers, we set methylation data points outside the 3× inter-
quartile-range from the 25th and the 75th percentiles to
missing. The total number of probes available for analyses
were N = 468,828 at birth; N = 471,092 at childhood; and N
= 470,480 at adolescence.
Epigenome-wide association analyses (EWAS)
In ALSPAC, the final sample size at birth was N = 822
(25 cases and 797 controls); at childhood N = 848 (7
cases and 841 controls) and N = 813 (12 cases and 801
controls) at adolescence. The final sample only con-
tained singletons and no siblings. Only 2–3 cases over-
lapped across time points (Additional file 1: Figure S1).
This is to be expected as certain types of seizures, such
as febrile ones, are more common in the first years of
life and children diagnosed with epilepsy might have re-
ceived treatment to prevent further seizures. Moreover,
the age of onset of some forms of epilepsy is between
childhood and adolescence [29], explaining why some
children might have had their first seizures in their ado-
lescence. Fifty-eight out of a total of N = 817 adolescents
reported a lifetime experience of seizures.
We carried out four analyses. In analysis 1–3, we mod-
elled methylation at birth (model 1), childhood (model
2), and adolescence (model 3) as the outcome and seiz-
ure status (measured closest to each methylation time
point) as the exposure. To investigate the temporal sen-
sitivity of associations, we ran a final analysis (model 4),
in which we modelled lifetime seizure status (ever/never)
at 13 years as the exposure and methylation at adoles-
cence as the outcome (model 4). In all models (including
birth), methylation was defined as the outcome regard-
less of temporal order to keep model estimates consist-
ent and comparable. These EWAS were carried out in R
version 3.3.1 using the CpGassoc package [30].
All models were adjusted for age (when DNA methyla-
tion samples were taken), sex, prenatal maternal smok-
ing (Yes/No), and maternal education (university degree
Yes/No), each derived from ALSPAC maternal and
childhood questionnaires. The model using cord blood
data was additionally adjusted for gestational age and
birthweight. Unknown confounders and batch were ad-
justed using surrogate variable (SV) analysis [31]. Add-
itionally, we adjusted for cell counts using the
Houseman method for the childhood and adolescence
timepoints [32] and the Andrews and Bakulski method
for cord blood [33].
To summarize, the following models were applied:
Model 1: Methylation (cord) ~ seizure status (18
months) + age + sex + birthweight + gestational age +
maternal prenatal smoking + maternal education +
nucleated red blood cells + granulocytes + monocytes +
natural killer cells + B cells + CD4(+)T cells + CD8(+)T
cells +SV1 + … + SV15
Model 2: Methylation (childhood) ~ seizure status (8
years) + age + sex + maternal prenatal smoking + mater-
nal education + granulocytes + monocytes + natural
killer cells + B cells + CD4(+)T cells + CD8(+)T cells +
SV1 + … + SV13
Model 3: Methylation (adolescence) ~ seizure status
(11 years) + age + sex + maternal prenatal smoking +
maternal education + granulocytes + monocytes + nat-
ural killer cells + B cells + CD4(+)T cells + CD8(+)T
cells + SV1 + … + SV14
Model 4: Methylation (adolescence) ~ seizure status
(ever/never at 13 years) + age + sex + maternal prenatal
smoking + maternal education + granulocytes + mono-
cytes + natural killer cells + B cells + CD4(+)T cells +
CD8(+)T cells + SV1 + … + SV14
To correctly multiple testing, we present both Bonfer-
roni (0.05/number of probes) and FDR-corrected results.
Replication analyses
All CpG sites that were associated with seizures below at
least an FDR-correction threshold in ALSPAC were ana-
lyzed in an independent cohort to assess replication.
The Generation R Study is a population-based prospect-
ive cohort study conducted in Rotterdam, the
Netherlands, that recruited 9778 pregnant women with
an expected delivery date between April 2002 and Janu-
ary 2006. A total of 9749 children were born from these
pregnancies, and extensive data and biological samples
are available from the children and their mothers [34].
DNA methylation was measured in peripheral blood of
469 children aged 6 years (all singletons), using the Infi-
nium HumanMethylation450 (HM450) BeadChip as in
ALSPAC. Preparation and normalization of the Bead-
Chip array was performed according to the CPACOR
workflow in R [35] and methylation data points lower
than the 25th percentile − 3 × IQR and higher than the
75th percentile + 3 × IQR were excluded. In Generation
R, seizure events were measured using the answer “yes”
to the question “During the past 5/6 years, did your child
ever have a seizure/febrile convulsion?” asked to the
mothers when the children were 6 years of age. The final
sample size was N = 432, with 19 participants affected
by seizures and 413 unaffected (Additional file 1: Table
S1). Linear models similar to model 2 were run in Gen-
eration R on EWAS FDR-corrected methylation sites
and on BDNF probes. The covariates were measured
and categorized similarly to the analyses carried out in
ALSPAC. The results in ALSPAC and Generation R
where also meta-analyzed using METAL [36], using in-
verse variance weighting.
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Mendelian randomization analyses
To assess the causal link between DNA methylation and
the occurrence of seizures, we performed two-sample
Mendelian randomization (MR) using the EWAS results
for the CpG sites with FDR-corrected p values < 0.05 in
ALSPAC. Two-sample MR was performed using the
MR-Base online platform (http://www.mrbase.org/, last
accessed 06-06-2018) [37], the MRInstruments R pack-
age (https://github.com/MRCIEU/MRInstruments, last
accessed 06-06-2018), and the TwoSampleMR R package
(https://github.com/MRCIEU/TwoSampleMR, last
accessed 06-06-2018).
Three MR analyses were performed. (1) To investigate
the causal effect of DNA methylation on the risk of epi-
lepsy, we performed two-sample MR with DNA methy-
lation as exposure and a diagnosis of epilepsy as
outcome. For the genotype-exposure associations, we
searched for methylation quantitative trait loci (mQTLs),
i.e., genetic variants that are associated in cis with DNA
methylation (i.e., within 1Mb either side from the CpG
site), using the mQTL database (http://www.mqtldb.
org/, last accessed 06 June 2018) [38], restricting the
search to the time point, at which the CpG site was as-
sociated with seizure status. For the genotype-epilepsy
association, we used the summary statistics for ICD-9
and ICD-10 codes for epilepsy or seizure in MR-Base
generated on UKBiobank data (last accessed 04 Decem-
ber 2018). (2) To analyze the causal effect of risk for
seizure/epilepsy on DNA methylation (i.e., reverse caus-
ation), we performed two-sample MR with epilepsy diag-
nosis or febrile/vaccine-related seizures as exposure and
DNA methylation as outcome. For the genotype-
exposure associations, we used the summary statistics
for the genome-wide significant SNPs from a published
GWAS meta-analysis on all epilepsies, focal epilepsy,
and genetic generalized epilepsy [10] and from a pub-
lished GWAS on febrile and MMR-vaccine-related sei-
zures (focussing on 6 replicated genome-wide significant
SNPs in Table1 of the original article) [39]. Odds ratios
(OR) and confidence intervals were reverted to log-odds
and standard errors to use in the two-sample MR ana-
lysis. The summary statistics for the genotype-outcome
associations were drawn from the mQTL database
(http://www.mqtldb.org/, last accessed 06 June 2018)
[38]. (3) To analyze the causal effect of seizure-
susceptible DNA methylation (exposure) on other health
outcomes, we first performed a hypothesis-free PheWAS
using the mQTLs for CpG sites associated with seizures
and the MR-Base online PheWAS tool to screen for po-
tentially affected health outcomes. Then, we performed
two-sample MR with methylation as exposure and the
health outcomes identified by the PheWAS to estimate
the magnitude of the effect. We also performed a
hypothesis-driven two-sample MR on other
neurodevelopmental outcomes previously found to associ-
ate with seizures, i.e., autism, intelligence, and education.
Results
For a flowchart and overview of all results, see Add-
itional file 1:Figure S2.
Sample description
At 18 months, there were n = 25 children with the ex-
perience of seizures since birth and n = 797 without
(Table 1). Groups were comparable with respect to sex,
birthweight, gestational age, as well as maternal educa-
tion and smoking behavior during pregnancy. During
childhood, n = 7 children had experienced seizures be-
tween 7 and 8 years of age while 841 had not. Age at
blood draw was slightly higher in the children with sei-
zures (Table 1). Approaching adolescence, seizures had
been reported in n = 12 children, while n = 801 children
had not experienced seizures between 9 and 11 years of
age. There were slightly more females in the seizure
group. Fifty-eight adolescents reported a lifetime experi-
ence of seizures, while n = 759 had never experienced
seizures. Groups were comparable with respect to ma-
ternal smoking behavior, maternal education, and age at
blood draw. For correlation plots on seizure rates and all
covariates included in the final models specific to each
time point, see Additional file 1: Figures S3
Epigenome-wide association analyses
We did not identify any CpG sites that fell below a Bon-
ferroni or FDR-adjusted P value threshold at birth
(Table 2 and Additional file 1: Figure S4). In childhood,
two CpG sites were associated with seizure status at an
FDR-corrected p value < 0.05 (cg10541930: beta = −
0.010, SE = 0.002, uncorrected p value = 4.32 × 10−8 and
FDR = 0.020; cg25557432: beta = 0.014, SE = 0.003, un-
corrected p value = 1.82 × 10−7 and FDR = 0.043), of
which cg10541930 was also below the Bonferroni thresh-
old (0.05/470,489 = 1.06 × 10−7). The first CpG is lo-
cated in an intergenic region, at the transcription start
site for a non-coding RNA, while the second lies up-
stream of the gene MACROD2 involved in DNA repair.
In adolescence, we found one CpG site that fell below
a Bonferroni threshold of 0.05/470,479 = 1.06 × 10−7,
cg13974632 (beta = 0.053, SE = 0.010, uncorrected p
value = 5.55 × 10−8 and FDR = 0.026), while another
two CpG sites passed an FDR threshold only
(cg15810326: beta = 0.014, SE = 0.003, uncorrected p
value = 1.19 × 10−7 and FDR = 0.028; cg16983916: beta
= − 0.056, SE = 0.011, uncorrected p value = 1.79 × 10−7
and FDR = 0.028; Fig. 2a). The first CpG site is located
in the first exon of the brain-derived neurotrophic factor
(BDNF). The experience of seizures was associated with
increased DNA methylation at this site (Fig. 2b). The
Caramaschi et al. Clinical Epigenetics            (2020) 12:8 Page 5 of 13
Table 1 ARIES sample characteristics
Characteristic Birth Childhood Adolescence Adolescence (lifetime exposure)
With
seizures
Without
seizures
Total With
seizures
Without
seizures
Total With
seizures
Without
seizures
Total With
seizures
(ever)
Without
seizures
(ever)
Total
N 25 797 822 7 841 848 12 801 813 58 759 817
Sex (%F) 44% 51% 51% ND 50% 51% ND 51% 52% 52% 51% 51%
Age at methylation in
years (SD)
NA 7.69
(0.36)
7.44
(0.13)
7.45
(0.14)
17.65
(0.86)
17.11
(1.04)
17.12
(1.04)
17.16
(1.01)
17.10 (1.05) 17.10
(1.04)
Age at seizure
assessment in years
(SD)
1.54
(0.12)
1.52
(0.06)
1.52
(0.07)
8.60
(0.03)
8.66
(0.16)
8.66
(0.16)
11.70
(0.08)
11.71
(0.12)
11.71
(0.12)
13.12
(0.09)
13.15 (0.17) 13.43
(1.05)
Birthweight in g (SD) 3498.80
(545.54)
3495.08
(478.18)
3495.20
(480.00)
NA NA NA
Gestational age in
weeks (SD)
39.80
(1.50)
39.55
(1.48)
39.56
(1.48)
Maternal smoking
(%Y)
ND 13% 14% ND 12% 13% ND 13% 13% 14% 13% 13%
Maternal education
(%Uni)
32% 20% 21% ND 21% 21% ND 22% 22% 28% 22% 22%
ND not disclosed due to cohort restrictions, NA not applicable
Table 2 EWAS results. Top CpG sites for the three time-points: birth, childhood, and adolescence (cross-sectional and lifetime
exposure)
Time point ProbeID Beta SE P value FDR Bonferroni Chromosome Position Gene
Birth cg07504545 − 0.042 0.008 2.32 × 10−07 0.109 0.109 1 203456019 PRELP
cg04977770 − 0.054 0.011 7.15 × 10−07 0.168 0.335 17 79846763 THOC4
cg23625106 − 0.023 0.005 1.47 × 10−06 0.193 0.689 8 61789727
cg08461451 − 0.036 0.008 1.73 × 10−06 0.193 0.812 19 2295092 LINGO3
cg06367149 0.057 0.012 2.08 × 10−06 0.193 0.973 15 61254575 RORA
cg13396019 − 0.026 0.005 2.57 × 10−06 0.193 1.000 1 220564510
Childhood cg10541930 − 0.010 0.002 4.32 × 10−08 0.020 0.020 10 131909085
cg25557432 0.014 0.003 1.82 × 10−07 0.043 0.086 20 13976117 MACROD2
cg11317171 0.002 0.000 1.34 × 10−06 0.190 0.633 19 5623025 SAFB2;SAFB
cg06447795 0.090 0.019 1.62 × 10−06 0.190 0.761 20 36793996 TGM2
cg02389501 0.078 0.016 2.59 × 10−06 0.191 1.000 7 93757948
cg13647052 0.018 0.004 2.82 × 10−06 0.191 1.000 12 2800382 CACNA1C
Adolescence cg13974632 0.053 0.010 5.55 × 10−08 0.026 0.026 11 27740813 BDNF
cg15810326 0.014 0.003 1.19 × 10−07 0.028 0.056 4 148605127 PRMT10
cg16983916 − 0.056 0.011 1.79 × 10−07 0.028 0.084 7 156159713
cg11510269 0.007 0.001 5.18 × 10−07 0.050 0.244 12 123011761 RSRC2;KNTC1
cg17130518 0.052 0.010 5.33 × 10−07 0.050 0.251 7 76825482 CCDC146;FGL2
cg06222062 0.095 0.019 6.79 × 10−07 0.053 0.319 1 20396690 PLA2G5
Lifetime cg20162381 0.004 0.001 9.22 × 10−07 0.159 0.434 12 3310097 TSPAN9
cg20156774 − 0.028 0.006 1.52 × 10−06 0.159 0.717 6 32803500 TAP2
cg12888660 0.003 0.001 1.72 × 10−06 0.159 0.811 12 122018449 KDM2B
cg15031661 0.006 0.001 1.91 × 10−06 0.159 0.897 1 240256603 FMN2
cg17233506 − 0.031 0.006 2.21 × 10−06 0.159 1.000 17 46608293 HOXB1
cg18108087 0.010 0.002 2.32 × 10−06 0.159 1.000 1 59762112 FGGY
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other two CpG sites were located in the first exon of
Protein Arginine Methyltransferase 10 (PRMT10) and in
an intergenic region, respectively.
A sensitivity analysis where we adjusted for fewer cell types
to avoid overfitting (i.e., we omitted CD8+ T cell propor-
tions) showed similar association estimates in the probes at
FDR < 0.05 in the main EWAS (Additional file 1:Table S2).
No CpG site could be identified to be associated with
lifetime seizure experience. Inspection of QQ plots and
lambdas close to 1 gave little indication for an inflation
of test statistics (Additional file 1: Figure S5).
When testing the association of the significant CpGs
at childhood or adolescence across the other age ranges,
the effect sizes were much smaller, not significant after
correction for multiple comparisons, and for some CpGs
in the opposite direction. (Additional file 1: Table S3).
Replication in the Generation R Study
For replication, we focused on five CpG sites: two that
passed FDR correction in childhood and three that
passed FDR correction in adolescence. As one of the
CpG sites in adolescence was located in the gene BDNF,
which is a key driver in neuronal growth and has been re-
peatedly linked to epilepsy [40, 41], we expanded our search
space to include all CpG sites annotated to BDNF (n = 73).
None of the five CpG sites were associated with sei-
zures in Generation R during childhood. Although the
direction of effect suggested some degree of concord-
ance, all but one beta coefficient were a factor of 10
smaller and p values ranged between 0.1 and 0.8. (Add-
itional file 1: Table S4 and Fig. 3). When ALSPAC and
Generation R results for these five probes where meta-
analyzed together, all CpGs except for cg16983916
showed evidence of methylation differences (p value <
0.05/77 = 0.0006, Additional file 1: Table S4).
Investigating all 73 CpG sites annotated to BDNF,
none replicated based on a correction for 73 tests. We
observed only a weak correlation of all 73 regression
betas between cohorts (rho = 0.046, p value = 0.70 based
on adolescence results in ALSPAC and childhood results
in Generation R; Additional file 1: Table S4 and
Additional file 1: Figure S6). However, five CpG sites
Fig. 2 a Miami plot displaying the EWAS results by chromosome in adolescence. Positive values on y-axis indicate -log(p values) of
hypermethylated sites, whereas negative values on the y-axis indicate -log(p values) of hypomethylated sites (the sign of the y-axis values has
been changed to reflect this). Bonferroni cut-off line in red. b Boxplot of methylation levels at the BDNF-linked CpG cg13974632 (adjusted for
covariates). c Causal estimate for the effect of genetic generalized epilepsy on cg13974632 (BDNF). Individual SNP results in black and overall
causal estimates in red. d Leave-one-out analysis of the causal estimate for the effect of genetic generalized epilepsy on cg13974632 (BDNF). IVW
inverse variance weighted
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were significant at a nominal level. When ALSPAC and
Generation R results for these 73 probes where meta-
analyzed together, there was evidence for methylation
differences in 2 CpGs (p < 0.05/77 = 0.0006, Additional
file 1: Table S4). These were cg13974632, the top hit
from the EWAS, and cg15313332, 20Kb upstream.
Cross-tissue concordance in DNA methylation
We queried three independent databases to investigate
blood-brain concordance in DNA methylation for all five
CpG sites that passed FDR correction in ALSPAC. Based
on data from more than 122 pre-mortem blood samples
and paired post-mortem brain tissue [42], cross-tissue
correlation was strongest for BDNFcg13974632 (r = 0.39)
between blood and brain tissue from the entorhinal cor-
tex, followed by tissue from the prefrontal cortex (r =
0.27); Additional file 1: Figure S7A-E. Compared to
BDNFcg13974632, the remaining four CpG sites showed
correlations, which were generally weaker for tissue from
the prefrontal and entorhinal cortex. Cross-tissue corre-
lations based on a smaller sample of 16 individuals [43]
reported different correlation profiles (Additional file 1:
Figure S7F-G). In this dataset, the blood-brain correl-
ation was strongest for MACROD2cg25557432 in Brod-
mann Area BA20 (temporal cortex, rho = 0.48) and BA7
(parietal cortex, rho = 0.43), and for cg15810326 in
BA20 (rho = 0.31), whereas there was little evidence of a
positive correlation for the other sites in either BA10
(prefrontal cortex), BA20 or BA7.
Cross-tissue blood-brain correlations in a third dataset
of 12 epilepsy patients [44] were consistent with the lar-
ger dataset, although not discriminating between brain
regions (BDNFcg13974632: rho = 0.28, p = 0.42;
PRMT10cg15810326: rho = − 0.0, p = 0.94; cg16983916:
rho = 0.09, p = 0.81; cg10541930: rho = 0.32, p = 0.36;
MACROD2cg25557432: rho = 0.45, p = 0.19). Although the
correlation coefficients were similar to the larger dataset
(N = 122), in this smaller dataset (N = 12), there was
only 9% power to detect a correlation as low as 0.2 at
alpha = 0.05 and 26% power to detect a correlation of
0.4.
Based on data available via the Genotype-Tissue Ex-
pression (GTEx; www.gtexportal.org) project, we investi-
gated tissue-specific gene expression for genes linked to
the five FDR-corrected CpG sites. BDNF appeared to be
expressed in the brain and other tissues with highest ex-
pression in the cerebellum, while very low expression
was found in blood. MACROD2 is predominately
expressed in lymphocytes; PRMT10 is mainly expressed
in the ovaries (Additional file 1: Figure S8).
Mendelian randomization analyses
Uni- and bi-directional two-sample MR was performed
to investigate the effect of DNA methylation on seizure
occurrence and the effect of seizures on DNA methyla-
tion. We used genetic associations with febrile and
vaccine-related seizures and genetic associations with
epilepsy. The latter more generally includes the types of
seizures observed in our study (e.g., febrile and non-
febrile) [45]. As full genome-wide summary statistics
were only available for epilepsy, but not for febrile and
vaccine-related seizures, we could not perform the two-
sample MR to estimate the causal effects of methylation
on seizures. We identified only one cis-mQTL, which
could be used as instrument for DNA methylation. In
detail, the SNP rs10258194 was associated in cis with
cg16983916 (effect allele = T, beta = 0.25, SD = 0.04, p =
2.33 × 10−10) after excluding other SNPs due to linkage
disequilibrium. For the other CpG sites, either trans-asso-
ciations (further than 1Mb from the CpG site) or no asso-
ciations were identified. Two-sample MR indicated only
weak evidence for causal effects of DNA methylation at
cg1698369 (Additional file 1: Table S5) on epilepsy.
For the reverse (i.e., epilepsy/seizure affecting DNA
methylation), there were 9 SNPs to be used as instru-
ments for epilepsy from a previous GWAS meta-analysis
on all epilepsies, focal epilepsy, and genetic generalized
epilepsy, although only up to four SNPs were used in
any one analysis due to availability of summary statistics.
Six SNPs were identified as instruments for febrile/vac-
cine-related seizures, although only 5 were used.
Fig. 3 Regression betas in the discovery cohort ALSPAC (x-axis)
versus betas in the replication cohort Generation R (y-axis), plotted
for the five most significant probes at each timepoint. The analysis
in Generation R was conducted using blood DNA methylation data
from children at around 6 years of age and their experience of
seizures before that age (N = 19 with seizures, N = 413 without
seizures) and was run including the same covariates as in the
discovery cohort
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Additional file 1: Table S6 shows the results of the two-
sample MR analysis performed using different methods
to investigate the causal effect of epilepsy on DNA
methylation at the five CpG sites identified in the
EWAS. For cg13974632 (BDNF), there was some evi-
dence for a positive association of genetic generalized
epilepsy with increased DNA methylation using the
weighted median method (Fig. 2c, d). All methods, in-
cluding MR-Egger, suggested a positive effect of genetic
generalized epilepsy on cg13974632, although these ana-
lyses were based on only 3 genetic instruments, and con-
fidence intervals were large, particularly for MR-Egger.
The leave-one-out analysis indicated that this effect was
not driven by a particular genetic variant, providing little
evidence for a violation of MR assumptions. This associ-
ation did not survive a correction for multiple testing
and seemed to be specific for genetic generalized epi-
lepsy (i.e., the effect was not reproduced using focal epi-
lepsy or “any epilepsy” as an exposure). There was no
evidence for associations with any other CpG sites.
The two-sample MR analysis of the effects of febrile
and vaccine-related seizures on methylation did not
show enough evidence of a causal association (Add-
itional file 1: Table S7).
To test the effect of seizure-associated methylation on
other health outcomes, we scanned for potentially rele-
vant health traits by performing a PheWAS (association
of genotype with all available outcomes) and, subse-
quently, two-sample MR using the only mQTL available,
rs10258194. As we used only one instrument, we could
not differentiate whether the associations were due to
causal effects or horizontal pleiotropy (i.e., the genetic
variant has an effect on the health outcome outside of
its effect on DNA methylation at the specific CpG). The
analysis revealed little evidence for associations between
rs10258194 and other health outcomes, both when ana-
lyzed in a hypothesis-free screening PheWAS across all
available outcomes (Additional file 1: Table S8) and
when analyzed in a two-sample MR with specified out-
comes (top outcomes from PheWAS and neurodevelop-
mental outcomes, Table 3).
Discussion
In this study, we observed associations between blood
DNA methylation and the occurrence of seizures in a
longitudinal pregnancy cohort study based in the UK.
Effects were specific to childhood and adolescence, with
little evidence for a relationship at birth or for lifetime
exposure to seizures. However, associations did not rep-
licate in an independent study sample based in the
Netherlands. The results are summarized in Additional
file 1: Figure S2.
This study has a number of strengths. First, in both
ALSPAC and Generation R cohorts, the information on
seizures was provided by the parents near the time of
occurrence, therefore reducing measurement error and
the possibility of recall bias. Secondly, repeated blood
sampling at different ages in ALSPAC, including birth,
allowed age-specific cross-sectional analyses. Thirdly,
these studies have collected extensive information from
obstetric records and reported socioeconomic factors
allowing adjustment for potential confounders, including
birth weight as well as maternal smoking during preg-
nancy and maternal education. Finally, we used a Men-
delian randomization approach as an alternative method
to control for unmeasured confounding and examine the
direction of observed associations.
Our results in the discovery cohort suggest a link be-
tween BDNF, a neurotrophin that is highly expressed in
the brain, and seizures and epilepsy, at a site where
blood and brain DNA methylation levels show corres-
pondence. Mendelian randomization analyses suggest a
potential causal effect of seizures on DNA methylation
in the BDNF gene. Although the implications of the as-
sociation with BDNF are interesting, the association was
not replicated. Studies conducted in animal models of
Table 3 Mendelian randomization analysis. Effects of DNA methylation at cg16983916 on non-epilepsy outcomes (PheWAS and
candidate outcomes)
Outcome Reference N Betaa S.E. P value (uncorrected)
Weight UK Biobankb 336227 0.016 0.009 0.067
Trunk fat-free mass UK Biobankb 331030 0.025 0.006 3.73 × 10−05
Standing height UK Biobankb 336474 0.029 0.007 2.90 × 10−05
Years of schooling Okbay et al. [46] 182286 0.008 0.008 0.317
Childhood intelligence Benyamin et al. [47] 12441 0.013 0.051 0.797
Autism Smoller et al. [48] 29415 − 0.008 0.113 0.946
Fluid intelligence score UK Biobankb 108818 0.119 0.036 0.001
College or University degree UK Biobankb 334070 0.013 0.004 0.004
aWald ratio
bUnpublished summary statistics from the UK Biobank. https://github.com/Nealelab/UK_Biobank_GWAS
and http://www.nealelab.is/blog/2017/9/11/details-and-considerations-of-the-uk-biobank-gwas
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epilepsy (reviewed in [49]) observed an upregulation of
BDNF immediately after experimentally induced sei-
zures. A study conducted on hippocampal tissue from
40 adult patients affected by mesial-temporal lobe epi-
lepsy showed increased or decreased BDNF expression,
compared to healthy individuals, depending on the re-
gion investigated and on the presence of psychiatric co-
morbidities [50]. Similarly, four isoforms of BDNF were
found to be highly expressed in brain hippocampal tissue
from adult epileptic patients compared to healthy con-
trols, although the effect was not explained by changes
in DNA methylation measured in the promoters of iso-
forms IV and VI [41] . It is to be noted that the associ-
ation reported in the current study was located further
upstream within the first intron of isoforms I, II, and III,
based on the latest gene characterization [41, 51]. More-
over, a recent family study investigating genome-wide
DNA methylation in peripheral blood, based on 15 trios
of parents and their offspring, where the child and one
parent, but not the other, were affected by generalized
genetic epilepsy, found evidence of neurotrophins in-
volvement, particularly BDNF, which was both hyper-
and hypomethylated [52]. In our study, we observed
hypermethylation in the BDNF gene (in the promoter or
within introns, depending on the isoform), which would
suggest decreased expression. This is in apparent con-
trast with some of the previous studies, but in line with
our Mendelian randomization analysis that also showed
some evidence of seizure-induced hypermethylation in
the BDNF gene when using generalized genetic epilepsy as
the exposure. The apparently contrasting findings in the
BDNF gene and the lack or reproducibility of this associ-
ation could be explained by the fact that BDNF expression
in blood is very low, but follow-up investigations in bio-
logical systems with multi-tissue characterization are re-
quired to elucidate this further.
We also show potential associations with other
methylation sites that have not been previously ob-
served, specifically in the MACROD2, the PRMT10
genes, and two intergenic sites. Single nucleotide
polymorphisms within MACROD2 have previously
been associated with autism, although with rather
weak evidence [53], and other brain-related traits
such as intelligence and mathematical abilities [54].
Individuals with de novo mutations in FBXO11, an
analogous of PRMT10, have been reported to show
intellectual disability and autism [55]. Although both
genes are predominantly expressed in non-neural tis-
sues, these studies suggest that MACROD2 and
PRMT10 could play a role in brain functioning, and
their methylation status could plausibly be involved in
seizures. However, as these associations were not rep-
licated, the involvement of DNA methylation in blood
at these sites needs to be further investigated.
The results of this study have to be seen in light of the
following limitations. First, despite this being the largest
epigenome-wide association study in childhood/adoles-
cence, the sample size was small considering the low
prevalence of seizures in the general population. Second,
our initial findings did not replicate in data from an in-
dependent cohort. However, this could also indicate that
the associations are specific to the time window exam-
ined in the discovery sample. For instance, the associ-
ation with BDNF methylation was specific to the
adolescence time point, while in Generation R data was
limited to childhood. Thirdly, we have relied on DNA
methylation measured in blood whereas seizures occur
within the brain. Availability of brain tissue for epi-
demiological research is very limited, and future studies
could follow-up our findings in animal models or post-
mortem brain tissues. Finally, the Mendelian
randomization analyses relied on a small number of
mQTLs (3 for epilepsy to BDNF methylation and 1 for
methylation to epilepsy and other health outcomes) and
therefore did not allow for sensitivity analyses aimed at
ruling out bias due to horizontal pleiotropy.
Conclusions
In conclusion, we show that the evidence of a link be-
tween seizures and blood DNA methylation in childhood
and adolescence is weak. Our study highlights the chal-
lenges of conducting epigenome-wide association studies
of seizures across different developmental periods and
warrants a careful analysis of the data in view of the lim-
itations of such study.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-019-0793-z.
Additional file 1: Figure S1. Overlap of cases across time points.
Figure S2. Overview of results. All models were adjusted for covariates as
specified in the main text (including cell composition and surrogate
variables). In MR analyses, epilepsy was chosen as a trait due to the
availability of GWAS summary data as well as febrile and MMR-vaccine-
related seizures. Figure S3. Plots displaying bivariate correlations be-
tween all variables included in the final models: (A) at birth, (B) during
childhood and (C-D) adolescence (cross-sectional and lifetime seizure ex-
posure, respectively). Figure S4. Miami plots displaying EWAS results: (A)
at birth, (B) during childhood and (C-D) adolescence (cross-sectional and
lifetime seizure exposure, respectively). The sign of the y-axis (-log(P-
values) has been changed to indicate positive and negative changes in
DNA methylation. Bonferroni cut-off line in red. Figure S5. Quantile-
quantile plots displaying potential test statistic inflation in the final
models (A) at birth, (B) during childhood and (C-D) adolescence (cross-
sectional and lifetime seizure exposure, respectively). Lambda was calcu-
lated using the regression method. Figure S6. Differences in DNA methy-
lation according to experienced seizures in ALSPAC and Generation R
(top panel) in the BDNF gene. The bottom panel shows the location of
the transcripts reverse strand. Figure S7. Cross-tissue correspondence of
CpG sites, passing FDR correction in ALSPAC, based on data available at
A-E) https://epigenetics.essex.ac.uk/bloodbrain and F-G) https://redgar598.
shinyapps.io/BECon. PFC = prefrontal cortex; STG = superior temporal
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gyrus; EC = entorhinal cortex; CER = cerebellum. Figure S8. Tissue-
specific expression of BDNF, MACROD2 and PRMT10, based on data avail-
able at www.gtexportal.org. Table S1. Sample descriptives of Generation
R. Table S2. Association estimates for FDR<0.05 probes re-analyzed with
adjustment for 5 cell types. Table S3. Association of DNA methylation
and the occurrence of seizures at CpGs with FDR<0.05 across all models.
Table S4. Replication in Generation R and meta-analysis. Table S5. Two-
sample MR analysis of the effect of DNA methylation on epilepsy
(method=Wald ratio). Table S6. Two-sample MR analysis of the effect of
epilepsy on DNA methylation. Table S7. Two-sample MR analysis of the
effect of febrile and vaccine-related seizures on DNA methylation. Table
S8. Top 50 associations with rs10258194 in MR_Base.
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